CORVUS PHARMACEUTICALS INC (CRVS)
Health Care · Immunooncology and T cell-targeted therapeutics · NASDAQ
A clinical-stage biopharmaceutical company developing targeted ITK inhibitors to modulate immune function for the treatment of cancer and inflammatory diseases.
What CORVUS PHARMACEUTICALS INC does
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing product candidates that target proteins critical to immune cell maturation and function. The company's lead candidate, soquelitinib (formerly CPI-818), is a selective, covalent ITK inhibitor designed to modulate T cell function for treating immune-mediated, inflammatory, and oncologic diseases. The pipeline includes soquelitinib in Phase 3 trials for relapsed T cell lymphomas and Phase 2 trials for atopic dermatitis, plus two additional candidates in clinical development for solid tumors.
Themes: Oncology / T cell lymphomas, Immunomodulation / T cell engineering, Atopic dermatitis and inflammatory diseases, Clinical-stage biopharmaceutical
Fundamentals
- Price$14.46 as of 2026-08-21 close
- Market cap$1.2B as of 2026-08-21
- 1-year return+173.3% 2025-08-21 close $5.29 → 2026-08-21 close $14.46
- P/En/a earnings data not available
- ROE-36.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.49 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CRVS compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CORVUS PHARMACEUTICALS INC looks technically
CORVUS PHARMACEUTICALS INC (CRVS) is trading 7.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 237 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 46.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 7.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +7.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.98 | $13.98 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $13.45 | $13.45 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 12.53. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 237 trading days ago — a "golden cross", a bullish long-term signal | 237 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 12.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 51.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($12.80 to $15.72) — its "stochastic" reading is 57 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 56.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $26.95 | $26.95 |
|---|---|---|
| From the 52-week high | it is 46.3% below its 52-week high (its highest price of the past year) | -46.4% |
| Above the 52-week low | it is 187.5% above its 52-week low (its lowest price of the past year) | +187.5% |
| Below the 52-week high | it is 46.3% below its highest point of the past year | 46.4% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 52 trading days ago | 52 sessions |
| All-time high | its highest closing price on record is $26.95 (set on 2026-01-23) | $26.95 |
| Given back of the 52-week move | over the past year its closes ranged ($5.19 to $25.52), and it has given back around half of its rise from last year’s low — 54% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $12.31 to $12.96. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 54.4% |
| From the all-time high | it is 46.3% below its all-time high | -46.4% |
| Nearest price level | it is trading 2.8% above a support level at $14.05 — a price it turned at twice since 2026-04-29, most recently on 2026-05-27. Since 2024-08-21 it has 11 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.8% |
| All-time low | its lowest closing price on record is $0.607 (set on 2023-03-28) | $0.607 |
| Above the all-time low | it is 2282.2% above its all-time low | +2,282% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 76% of it) | 24th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7393 between its high and its low — about 5.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7393 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.59 and $15.63 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.59 – $14.11 – $15.63 |
| Typical daily range (% of price) | its price moves about 5.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.1% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges above its 200-day average price (7.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.54× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.3% |
|---|---|---|
| Open gap | it gapped 4.6% above the previous close 43 sessions ago and has not traded back through the level it left behind at 11.91 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.6% |
| Gap filled | a 2.5% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.4 percentage points (the stock lost 0.1% while the market gained 2.3%) | -2.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 7.5 percentage points (the stock gained 10.6% while the market gained 3.1%) | +7.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 23.8 percentage points (the stock lost 12.7% while the market gained 11.1%) | -23.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 152.9 percentage points (the stock gained 173.3% while the market gained 20.5%) | +152.9% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: lagging the market over 6 months — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.0% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.0% of the share price. | +0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 17% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $17.43 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -17.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $14.59 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -0.9% |
Price levels it has turned at before
CRVS last closed at $14.46 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $14.05 | Support | 2.8% below the last close | turned there twice · 2026-04-29 to 2026-05-27 |
| $12.88 | Support | 11.0% below the last close | turned there twice · 2026-03-20 to 2026-08-07 |
| $9.57 | Support | 33.8% below the last close | turned there twice · 2024-11-29 to 2025-12-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $12.53.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $18.09 and $21.53 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $12.53.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · lagging the market · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.13 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$33.14 range $27.00 – $42.00; median $32.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CRVS
- Consensus EPS estimate-$0.205 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: soquelitinib is in Phase 2/3 trials with no approved products, exposing the company to regulatory, efficacy, and safety uncertainties that could delay or halt development.","Capital requirements: as a clinical-stage company with no revenue, Corvus faces ongoing financing risk and depends on raising capital to fund continued clinical trials and operations.","Competitive landscape: ITK inhibitors and other T cell-targeted therapies are being pursued by larger pharmaceutical companies, creating intellectual property and market adoption risks."]
What changed in the latest 10-Q
AI-assisted comparison of CRVS's 10-Q filed 2026-05-07 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to audited consolidated financial statements for year ended December 31, 2025, filed March 12, 2026 (newer filing)
- List of diseases expanded to include 'hidradenitis suppurativa' in the overview
- Reference to 'potentially registrational Phase 3 clinical trial' language (newer filing)
- Disclosure that Phase 1b/2 atopic dermatitis trial in China is being conducted by Angel Pharmaceuticals (newer filing)
- Reference to December 2024 publication in npj Drug Discovery with specific key results about soquelitinib selectivity and Th2/Th1 skewing (newer filing)
- Product Candidate Pipeline table section added (newer filing)
- Removed:
- Reference to audited consolidated financial statements for year ended December 31, 2024, filed March 25, 2025 (older filing)
- Disease list order changed: 'cancers, immune mediated diseases and inflammatory diseases' removed from specific order (older: 'cancers' listed first)
- Mention of 'allergy' as a separate disease indication removed from the overview list
- Reference to Phase 1 trial language: 'randomized, placebo controlled Phase 1 trial in patients with atopic dermatitis' (older filing)
- Language 'tumor cell killing' changed to 'tumor cell eradication'
- Section titled 'Soquelitinib for treatment of T cell lymphomas' and detailed description of Phase 1/1b trial design removed from newer filing excerpt
- Mention of 'Il-31' cytokine removed from the list of Th2/Th17 produced cytokines
- Phrase 'and fight infection' removed from description of interferon gamma and tumor necrosis factor
- Language 'a process known as Th1 skewing' removed (shorter version in newer filing)
- Reworded:
- Disease indication wording: 'hidradenitis suppurativa' added between 'atopic dermatitis' and 'asthma' in newer filing
- Trial status changed from 'entered a registrational, Phase 3 clinical trial' to 'enrolling patients in a potentially registrational Phase 3 clinical trial'
- Atopic dermatitis trial changed from 'Phase 1 trial' to 'Phase 2 trial' in the overview paragraph
- Th2/Th17 cells description changed from 'are the cells that produce the cytokines' to 'produce the cytokines' (removal of 'are the cells that' phrase)
- Notes:
- Newer filing excerpt appears truncated at the end of soquelitinib description, ending mid-sentence regarding December 2024 publication results
- Older filing excerpt also appears truncated, ending mid-section on Phase 1/1b trial design
- Direct comparison of full section content limited due to truncation in both filings
Risk Factors
- Added:
- In Risk Factor Summary, added punctuation around 'Food and Drug Administration' abbreviation reference in the foreign trials risk factor (newer filing filed 2026-05-07)
- Updated financial data showing net loss of $15.3 million for year ended December 31, 2025 (newer filing filed 2026-05-07)
- Added quarterly financial results: three months ended March 31, 2026 net loss of $13.7 million and three months ended March 31, 2025 net income of $15.2 million (newer filing filed 2026-05-07)
- Updated accumulated deficit to $426.0 million as of March 31, 2026 (newer filing filed 2026-05-07)
- Removed:
- Removed net loss figures for years ended December 31, 2022 ($41.3 million) which were in older filing (filed 2025-11-04)
- Removed nine-month period results for September 30, 2025 and 2024 (net loss of $3.0 million and $50.2 million respectively) from older filing (filed 2025-11-04)
- Removed accumulated deficit figure of $400.0 million as of September 30, 2025 (filed 2025-11-04)
- Reworded:
- In a risk factor about serious complications, changed 'results of operations' to 'prospects, results of operations' (filed 2026-05-07 vs filed 2025-11-04)
- In the main section heading, older filing referred to 'operating results' while newer filing uses 'results of operations' in one risk factor statement
- Clarified reference to 'Food and Drug Administration ("FDA")' in foreign trials bullet point in newer filing (2026-05-07) versus just 'FDA' in older filing (2025-11-04)
- Notes:
- Text appears truncated at end of both filings, preventing full comparison of the complete risk factor section
- Financial figures represent standard quarterly/annual updates rather than substantive risk disclosure changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days.
- Last 90 days1 buy ($250236) · 0 sells — 1 buying insider
- Last 180 days3 buys ($333689) · 0 sells — 2 buying insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-11. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CRVS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CRVS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 10,724,007
- Reported value $156,892,220
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CRVS had 18,310,256 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CRVS had 21.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 22.5 days to cover at the same settlement.
- Reported short interest (shares) 18,310,256
- Short interest (% of shares outstanding) 21.8%
- Prior settlement (shares) 18,061,919
- Reported change 1.37%
- Days to cover (reported) 22.5
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (GILD)
- Celgene (now part of Bristol Myers Squibb) (BMY)
- Amgen (AMGN)
- Juno Therapeutics (part of Celgene/BMY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CRVS vs…
Frequently asked questions
What does CORVUS PHARMACEUTICALS INC (CRVS) do?
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing product candidates that target proteins critical to immune cell maturation and function. The company's lead candidate, soquelitinib (formerly CPI-818), is a selective, covalent ITK inhibitor designed to modulate T cell function for treating immune-mediated, inflammatory, and oncologic diseases.
What sector is CORVUS PHARMACEUTICALS INC (CRVS) in?
CORVUS PHARMACEUTICALS INC (CRVS) is classified in the Health Care sector. Its industry is Immunooncology and T cell-targeted therapeutics. It trades on NASDAQ.
Who are CORVUS PHARMACEUTICALS INC's (CRVS) competitors?
Notable peers of CORVUS PHARMACEUTICALS INC (CRVS) include Gilead Sciences, Celgene (now part of Bristol Myers Squibb), Amgen and Juno Therapeutics (part of Celgene/BMY). This peer set is informational only — not financial advice.
Is CORVUS PHARMACEUTICALS INC (CRVS) overbought or oversold right now?
CORVUS PHARMACEUTICALS INC (CRVS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CRVS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.